The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh ImpactUpdated•Originally published 23 February 2026•Updated 23 February 2026•

1 min read

Gilead Sciences to Acquire Arcellx for $7.8 Billion in Major Biotech Deal

Key Facts

1Gilead Sciences agreed to buy Arcellx for $115 per share in cash.

3 months ago

Version History

Version 13 months ago

What changed: Added market context indicating that Arcellx's gains occurred despite a general decline in the equity markets.

Gilead Sciences (GILD) has reached a definitive agreement to acquire cancer-therapy developer Arcellx (ACLX) in an all-cash transaction valued at approximately $7.8 billion. Under the terms of the deal, Gilead will pay $115 per share, plus a Contingent Value Right (CVR) worth an additional $5 per share contingent upon future sales targets. Following the announcement, Arcellx shares surged by approximately 80% in premarket trading, a significant gain that occurred despite a broader downturn in the equity markets. This strategic move is designed to significantly bolster Gilead's oncology pipeline and expand its footprint in advanced cancer treatments. Analysts expect this large-scale M&A activity to drive positive sentiment across the broader biotech sector and impact indices such as IBB and XBI, even amidst general market volatility.